Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $43.35 | Total: $216.75 |
| 1 | 10 | $36.72 | Total: $367.20 |
| 1 | 25 | $31.11 | Total: $777.75 |
| 1 | 50 | $26.52 | Total: $1,326.00 |
| 1 | 100 | $22.95 | Total: $2,295.00 |
Overview
AOH1996 is an orally active ligand for the replicasome component PCNA (proliferating cell nuclear antigen), targeting the transcription-replication conflict (TRC). It interferes with the interaction of PCNA with its binding proteins, leading to DNA replication stress and apoptosis. AOH1996 causes proteasome-dependent rpb1 degradation and lethal DNA damage by stabilizing the interaction between PCNA and RNA polymerase II, and acts synergistically with DNA damaging agents to inhibit tumor cell growth.
Chemical Properties
| Molecular Formula | C26H22N2O4 |
| Molecular Weight | 426.46 |
| CAS Numbers | 2089314-64-5 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C(NCC(NC1=C(OC2=CC(OC)=CC=C2)C=CC=C1)=O)(=O)C=3C4=C(C=CC3)C=CC=C4 |
Storage and Handling
0C Short Term, -20C Long Term
References
Gu L, et al. Pharmacological targeting of transcription-replication conflict leads to anti-cancer efficacy with minimal side effects in preclinical models. Cancer Research. 2021; 81[13_Supplement] 1269-1269.